AI leverage meets expansion into gastrointestinal health
- Management raised full-year 2026 revenue guidance to between $856 million and $860 million after a strong second quarter.
- The company generated $100 million in free cash flow in the second quarter of 2026.
- Hinge acquired Cylinder Health for $105 million in cash to expand into gastrointestinal care.
- Lives covered in the small and medium business segment grew by more than 100 percent in the first half of 2026.
- The FDA has an ongoing inquiry into TrueMotion, the core AI motion tracking technology of the company.
Fast growth, broader platform
Hinge Health is proving that digital care can scale. Second quarter 2026 results showed strong growth, with the company raising full-year revenue guidance to between $856 million and $860 million and generating $100 million in free cash flow.
The bull case centers on expanding the total addressable market. Hinge is adding gastrointestinal care through a $105 million cash acquisition of Cylinder Health. This multi-product strategy, combined with over 100 percent growth in the small and medium business segment, creates a strong competitive moat.
The bear case rests on regulatory and competitive threats. State telehealth rules still matter, but the bigger worries are a stronger Sword and Kaia rival and the FDA inquiry into TrueMotion. Changes to pricing models could also create revenue misses if engagement drops.
The next year should answer several key questions. Watch the integration of Cylinder Health for a 2027 rollout, HingeSelect adoption, the Migraine Care Program launch, and the FDA TrueMotion process.
Employers pay when members engage
Hinge runs a B2B2C model. It sells to businesses and health plans, then delivers care to the people covered by those plans. Main customers are self-insured employers, with rapid new growth coming from small and medium businesses.
The company sells annual subscriptions. Clients usually pay only after an eligible person uses the program in a billable way. Hinge then recognizes revenue over the 12-month subscription period of the member.
Pricing is shifting. About 80 percent of contracted lives are on engagement-based pricing, and the company is moving some clients to an alternative engagement-based model. That can make revenue less predictable if member use is different from expectations.
The model works best when Hinge keeps members active, proves savings to clients, and renews large contracts. It breaks if employers see weak engagement, if health plans push back on billing, or if regulators force changes to care delivery.
More than remote PT
Core MSK platform
This is the main business. It covers joint and muscle care, from new injuries to chronic pain to post-surgery rehab.
Cylinder Health
Acquired in 2026 for $105 million, this expands the Hinge platform into the gastrointestinal health space.
TrueMotion
TrueMotion uses AI-powered motion tracking to guide exercise and reduce the need for constant human review. It is central to the scale advantage of the company, but it is also the subject of an FDA information request.
Enso
Enso is an FDA-cleared wearable device for pain relief. It also supports newer programs like migraine care.
Robin
Robin is an always-on AI care assistant. Its job is to help members get support faster while lowering the workload on the care team.
HingeSelect
HingeSelect is an in-person provider network for MSK care. Management has said it does not expect much revenue impact until at least 2027, but it could become a moat if it scales well.
Women’s pelvic health and menopause
Hinge expanded women’s pelvic health and added a movement-based menopause program in 2025. These programs help widen the platform beyond standard physical therapy.
Migraine Care Program
The Migraine Care Program launched in May 2026 and uses Enso. Management said it had already been adopted by over 125 enterprise clients.
One platform, several buyers
For Q2 2026, Hinge disclosed subscription revenue from its platform and said it generates substantially all revenue in the United States. It does not disclose exact revenue shares by employer, health plan, Medicare Advantage, or federal channel.
What could go wrong
FDA TrueMotion review
High impact · Medium oddsThe FDA requested information about how Hinge markets TrueMotion and why the company believes it does not need FDA clearance or a prescription. If the FDA disagrees, Hinge may need to change labeling, seek clearance, slow product features, or face added costs. This matters because TrueMotion is part of the AI scale story of the company.
Pricing model surprise
Medium impact · Medium oddsHinge is moving more lives to engagement-based pricing, including a newer model that management says can be hard to predict. If members do fewer billable sessions than expected, revenue can come in lower even if the client count grows. This could also make quarterly results harder to read.
Sword and Kaia pressure
High impact · Medium oddsSword Health acquired Kaia Health in January 2026, creating a larger rival in digital MSK care. Bigger competitors can pressure prices, win employer bids, or copy features. Hinge must show that its AI, outcomes data, and partner access keep it ahead.
Telehealth and practice rules
Medium impact · Medium oddsHinge delivers care across state lines, where physical therapy, telehealth, and corporate practice of medicine rules can differ. Illinois risk eased in 2025 after a restrictive amendment was reversed, but other states can still create friction. More rules could raise costs or limit how care teams work.
HingeSelect execution
Medium impact · Medium oddsHingeSelect adds an in-person provider network to a digital-first model. It could deepen the moat, but it also adds provider oversight, quality control, and consumer protection risk. Management has said revenue impact is not expected to be meaningful until at least 2027.
In one breath
What does Hinge Health do?
Hinge Health provides digital care for muscle, joint, and gastrointestinal conditions. Members use software, AI motion tracking, wearables, and support from licensed care teams.
Who pays Hinge Health?
Most revenue comes from self-insured employers. Hinge also sells through health plans, Medicare Advantage, and federal insurance plans.
Why is the FDA inquiry important?
TrueMotion is a core AI motion tracking tool for Hinge. If the FDA decides it needs clearance or a prescription, Hinge could face delays, added costs, or product changes.
Is Hinge Health profitable?
Hinge has shown strong operating leverage, generating $100 million in free cash flow in the second quarter of 2026. The main investor question is whether that leverage can continue as competition and regulation get tougher.
